EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib By Ogkologos - May 22, 2026 137 0 Facebook Twitter Google+ Pinterest WhatsApp Palbociclib Viatris is a generic of Ibrance which has been authorised in the EU since 2016 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR How My Navy Career Helped Shape My Positive Attitude During My... December 16, 2020 News digest – dinosaur bone cancer, YouTube junk food ad ban... August 8, 2020 GreaterGood Has Donated More Than 2 Million Masks to Frontline Workers... December 21, 2020 Wales: 4 in 10 with possible cancer symptoms didn’t contact GP June 17, 2021 Load more HOT NEWS Opinion: ‘UK cancer research could be set back years by COVID-19. We must act now’ Colonoscopy after Positive FIT Test Cuts Risk of Colorectal Cancer Death Mom Warns Others After Little Girl’s Skin Blisters From ‘Margarita Burn’ For Children with Retinoblastoma, Disparities Seen across the Globe
